Domain Associates — Full Portfolio

Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome.

BiotechHealthtechMedical DevicesSan Diego, US

Han Cao(Executive Officer)Gulsen Kama(Executive Officer)MOMark Oldakowski(Executive Officer)inJDJonathan Dixon(Executive Officer)inRER. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)in

Board seatBHBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015

Co-investorsHUHudson Bay

Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis.

BiotechSan Diego, US

Ivy Zhang(Executive Officer)inSPSaundra Pelletier(Executive Officer, Director)inKelly Culwell(Executive Officer)inJJJustin J. File(Executive Officer)inAlexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)

Board seatKKKim Kamdar· per SEC Form D · $25M raise · filed May 2020

Co-investorsINInvescoWOWoodford Investment Management

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

AnhCo Nguyen(President and Chief Executive Officer)

Co-investorsDADag VenturesECEcoR1 CapitalHEHEALTHCARE ROYALTY PARTNERSKLKleiner PerkinsFIFidelity Investments

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

PSPaul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

BoardANAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCACardinal PartnersECEcoR1 CapitalSOSofinnova VenturesDODomain PartnersPOPolaris PartnersSASamsara BioCapital+1 more

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

HRHARITH RAJAGOPALAN(Executive Officer, Director)inJAY CAPLAN(Executive Officer, Director)inJay Caplan(Executive Officer, Director)inHRHarith Rajagopalan(Executive Officer, Director)inLDLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in

Co-investorsBEBessemer Venture PartnersCACatalio Capital Management, LPEMEmergent Medical Partners, LLPGEGeneral CatalystMIMITHRILMIMithril Capital Management+2 more

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAAAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in

BoardMansoor Mirza(Director)

Co-investorsAMaMoonEXExcelestar VenturesOUOUP (Osage University Partners)UPUpStart VenturesVIVivo CapitalCACatalyst Health Ventures

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsFOForesite CapitalPAPappas CapitalSOSofinnova VenturesVEvenBio PartnersBLBlackRockMPMPM BioImpact

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical Devices

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDMDamien McDevitt(President and Chief Executive Officer)in

Co-investorsARARCH Venture PartnersLILifeforce CapitalOROrbiMedEDEDB InvestmentsSESection 32FRFrazier Life Sciences+4 more

Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.

BiotechDigital HealthMedical DevicesSan Diego, US

DMDena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in

Co-investorsDNDns CapitalGRGreatPoint VenturesWIWittington VenturesMEMedical Excellence CapitalXBXB VenturesOSOS Fund

BiotechSan Mateo, US

AFAnthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in

BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatJTJesse Treu· per SEC Form D

Co-investorsPAPappas CapitalFIFidelity InvestmentsJEJennison AssociatesTHThird Rock Ventures

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.

BiotechHealthtechLa Jolla, US

PKPreston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)

BoardBrian H. Dovey(Director)in

Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015

Co-investorsCRCross Creek AdvisorsNENew Enterprise Associates (NEA)SOSofinnova VenturesDODomain Partners

HealthtechDuluth, US

Anthony V. Lando(Executive Officer, Director)inTMTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in

BoardRebecca B. Robertson(Director)

Board seatJTJesse Treu· per SEC Form D

Co-investorsACAccuitive Medical VenturesVEVersant Ventures

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Board seatBHBrian Halak· per SEC Form D · $125.5M raise · filed Jun 2026

Co-investorsVIVida VenturesLELeaps by BayerFOFoothill VenturesILIllumina VenturesMEMedical Excellence CapitalVIVivo Capital+1 more

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)DMDouglas Mayers(Executive Officer)inTATamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAIAisling CapitalALAltium CapitalAVAvego BioScience CapitalPOPontifax Venture CapitalAMAmzak HealthDEDelos Capital+8 more

bioMérieux develops in vitro diagnostic systems and molecular testing panels for pathogen detection in clinical, food safety, and pharmaceutical quality control settings.

BiotechHealthtechMedical DevicesSan Diego, US

Todd Myers(Executive Officer)inChristopher Hibberd(Executive Officer, Director)Kenneth Buechler(Director)Paul McPherson(Executive Officer, Director)

BoardJames Blair(Director)James Scopa(Director)

Co-investorsKAKaiser Permanente VenturesMOMoore Venture Partners

Biopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.

Co-investorsAIAisling CapitalASAsset Management CompanyCACanaan PartnersKLKleiner PerkinsSPSPRINGROCK VENTURESVAVantagePoint Capital Partners

ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.

AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US

PFPaul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)

BoardJKJustin Klein(Director)in

Co-investorsADAdjuvant CapitalGLGlobal BrainMOMoore Venture PartnersNENew Enterprise Associates (NEA)WIWindham Capital PartnersDODomain Partners+2 more

Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.

ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US

Stephen Loomis(Executive Officer)MFMary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)

BoardM Bolyard(Director)Brian Dovey(Director)in

Co-investors131315 CapitalAIAisling CapitalHEHealthCare Ventures, LLCLOLongwood FundRORoundTable Healthcare PartnersSPSplit Rock Partners

GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials.

BiotechHealthtechLogistics & Supply Chain

Co-investorsCRCross Creek Advisors

Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.

AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US

PGPaul Garofolo(CEO & Co-founder)NTNICK TAYLOR(Executive Officer)inNCNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in

BoardGGGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BBBARY BAILEY(Director)

Co-investorsARArtis VenturesABAbstract VenturesHEHemisphere Ventures LLCLOLongitude CapitalSTStarlight Ventures

BiotechRadnor, US

SBScott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)JHJoe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesCACanaan PartnersCOConnecticut InnovationsSOSofinnova VenturesFLFlare Capital Partners+1 more

San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.

Co-investorsARARCH Venture PartnersDEDecheng CapitalALALTITUDE LIFE SCIENCE VENTURESHIHillhouse CapitalNANan Fung Life Sciences

Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.

BiotechEnterprise SoftwareHardwareHealthtechWaltham, US

AUAnthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)MNMarc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)

Co-investorsARARCH Venture PartnersBABayMed Venture PartnersCRCross Creek AdvisorsEXExcel Venture ManagementHEHeran PartnersOAOak HC/FT+2 more